Stepwise evolution of therapy resistance in AML

Philippe Gui; Trever G Bivona

doi:10.1016/j.ccell.2021.06.004

Stepwise evolution of therapy resistance in AML

Cancer Cell. 2021 Jul 12;39(7):904-906. doi: 10.1016/j.ccell.2021.06.004. Epub 2021 Jun 24.

Authors

Philippe Gui¹, Trever G Bivona²

Affiliations

¹ Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: [email protected].
² Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: [email protected].

PMID: 34171262
DOI: 10.1016/j.ccell.2021.06.004

Abstract

Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multifaceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Disease Progression
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Neoplasm Recurrence, Local
Neoplasm, Residual
Tumor Microenvironment

Abstract

Publication types

MeSH terms

Grants and funding